Biotech Company Auxilium Explodes After Takeover Offer
The offer values Auxilium at $28.10 per share and is comprised of an equal mix of cash and Endo stock.
Endo's offer represents a 31% premium to Auxilium's closing price on Tuesday, and a 40% premium to the closing price of Auxilium over the last 30 days. In after hours trade on Tuesday Auxilium shares were trading as high as $30.70.
Following the announcement, Endo shares were also higher, up more than 4%.
The offer also follows an announcement from Auxilium last week that the company would cut 30% of its staff as part of cost-saving measures aimed as saving $75 million per year.
Auxilium's portfolio of drugs includes: edex®, an injectable treatment for erectile dysfunction, Osbon® ErecAid®, a device for aiding erectile dysfunction, STENDRA®, an oral erectile dysfunction therapy, TESTOPEL®, a long-acting implantable testosterone replacement therapy, XIAFLEX®, for the treatment of Peyronie's disease and XIAFLEX for the treatment of Dupuytren's contracture, among other drugs.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- An Ambani disruption in OTT: At just ₹1 per day, you can now enjoy ad-free content on JioCinema
- SC rejects pleas seeking cross-verification of votes cast using EVMs with VVPAT
- Ultraviolette F77 Mach 2 electric sports bike launched in India starting at ₹2.99 lakh
- Deloitte projects India's FY25 GDP growth at 6.6%
- Italian PM Meloni invites PM Modi to G7 Summit Outreach Session in June
- Markets rally for 6th day running on firm Asian peers; Tech Mahindra jumps over 12%